Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases
US9376393B2 · kind B2 · utility
0Cited by
2References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 4, 2013 |
| Grant date | Jun 28, 2016 |
| Priority date | — |
| Expiry date | Jan 4, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A new medical therapy, and more particularly certain quinoline compounds which are anti-angiogenic integrin aplha5beta1 inhibitors, for use in the treatment of fibrosis, or a fibrosis-related disease, such as a fibrotic disease affecting the lung, liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, stomach, large intestine, small intestine, colon, uterus, nervous system, testis, adrenal gland, artery, vein, biliary tract, or eye.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.